Your session is about to expire
← Back to Search
2X-121 + Dovitinib for Cancer
Study Summary
This trial is testing a new cancer drug to see how well it works and what side effects it has.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have recovered from my last surgery or cancer treatment side effects.I am not on any cancer treatments except for non-cancer related medications like insulin.I have a bleeding or clotting disorder or am on blood thinners.I am currently on antibiotics for an infection.I have an active heart condition.I have active hepatitis B or C.It has been over 2 weeks since my last surgery or treatment with G-CSF or GM-CSF.I need immediate relief treatment for my condition.My doctor agrees that my health allows me to join this study safely.I can take pills and do not have uncontrolled stomach issues.I understand the study and its risks.I am 18 years old or older.I am fully active and can carry on all my pre-disease activities without restriction.My cancer was confirmed through tissue or cell testing.I am not pregnant or breastfeeding.My brain condition is stable, and I've been on a steady or lower dose of steroids for over a week.I haven't had cancer, except for skin (non-melanoma) or cervical cancer, in the last 5 years.I am not pregnant or will use birth control during and after the study.
- Group 1: 2X-121 Monotherapy and Dovitinib in Combination with 2X-121 in Patients with Advanced Solid Tumors
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still patient vacancies available for this clinical trial?
"Affirmative. Clinicaltrials.gov reveals that this clinical trial, which was originally posted on October 20th 2022, is still in the process of enlisting participants. Approximately 40 individuals are required to be recruited from 2 distinct medical facilities."
What protective measures are taken to ensure the safety of patients when using 2X-121 Monotherapy and Dovitinib in Combination with 2X-121 for Advanced Solid Tumors?
"Due to a dearth of data assessing both safety and efficacy, 2X-121 Monotherapy and Dovitinib in Combination with 2X-121 received a score of 1."
What are the chief goals of this medical study?
"The main purpose of this clinical trial, monitored for up to two years, is to determine the maximum tolerated dose (MTD) of dovitinib in combination with 2X-121. Secondary objectives include assessing overall survival from treatment date until death or last known living status; measuring duration of response between first documented complete/partial response and disease recurrence/progression; and calculating objective response rate by proportion of subjects who achieved a complete or partial response per RECIST v1.1 guidelines."
What is the current enrollment capacity of this clinical trial?
"Confirmed. According to clinicaltrials.gov, the trial is still open for recruitment after being first advertised on October 20th 2022 and last updated 5 days ago. 40 participants are required from two separate medical centres."
Share this study with friends
Copy Link
Messenger